Patterns and Prevalence of BRCA1 and BRCA2 Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.2165433433946
   PubMed Web of Science ®Google Scholar
• Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global Cancer in Women: burden and Trends. Cancer Epidemiol Biomarkers Prev. 2017;26(4):444–457. doi:10.1158/1055-9965.EPI-16-085828223433
   PubMed Web of Science ®Google Scholar
• Trivers KF, Lund MJ, Porter PL, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control. 2009;20:1071. doi:10.1007/s10552-009-9331-119343511
   PubMed Web of Science ®Google Scholar
• Dickens C, Duarte R, Zietsman A, et al. Racial comparison of receptor-defined breast cancer in Southern African women: subtype prevalence and age-incidence analysis of nationwide cancer registry data. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2311–2321. doi:10.1158/1055-9965.EPI-14-060325143359
   PubMed Web of Science ®Google Scholar
• Haffty B, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006;24(36):5652–5657. doi:10.1200/JCO.2006.06.566417116942
   PubMed Web of Science ®Google Scholar
• Larsen MJ, Thomassen M, Gerdes A-M, Kruse TA. Hereditary breast Cancer: clinical, pathological and molecular characteristics. Breast Cancer. 2014;8:145–155. doi:10.4137/BCBCR.S1871525368521
   PubMedGoogle Scholar
• Wong-Brown MW, Meldrum CJ, Carpenter JE, et al. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2015;150(1):71–80. doi:10.1007/s10549-015-3293-725682074
   PubMed Web of Science ®Google Scholar
• Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20(9):2310–2318. doi:10.1200/JCO.2002.09.02311981002
   PubMed Web of Science ®Google Scholar
• Robertson L, Hanson H, Seal S, et al. BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer. 2012;106(6):1234–1238. doi:10.1038/bjc.2012.3122333603
   PubMed Web of Science ®Google Scholar
• NCCN Guidelines, Genetic/Familial high-risk assessment: breast, ovarian and pancreatic. Version 2.2021. Available from: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf. Accessed 223 2021.
   Google Scholar
• Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17(5):1082–1089. doi:10.1158/1078-0432.CCR-10-256021233401
   PubMed Web of Science ®Google Scholar
• Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer. 2000;83(10):1301–1308. doi:10.1054/bjoc.2000.140711044354
   PubMed Web of Science ®Google Scholar
• Peto J, Collins N, Barfoot R, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999;91(11):943–949. doi:10.1093/jnci/91.11.94310359546
   PubMed Web of Science ®Google Scholar
• Hartman AR, Kaldate RR, Sailer LM, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012;118(11):2787–2795. doi:10.1002/cncr.2657622614657
   PubMed Web of Science ®Google Scholar
• Fostira F, Tsitlaidou M, Papadimitriou C, et al. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Res Treat. 2012;134(1):353–362. doi:10.1007/s10549-012-2021-922434525
   PubMed Web of Science ®Google Scholar
• Young SR, Pilarski RT, Donenberg T, et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer. 2009;9:86. doi:10.1186/1471-2407-9-8619298662
   PubMed Web of Science ®Google Scholar
• Dite GS, Jenkins MA, Southey MC, et al. Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations. J Natl Cancer Inst. 2003;95(6):448–457. doi:10.1093/jnci/95.6.44812644538
   PubMedGoogle Scholar
• Nathanson KL, Wooster R, Weber BL. Breast cancer genetics: what we know and what we need. Nat Med. 2001;7(5):552–556. doi:10.1038/8787611329055
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Lynch HT, Neuhausen SL, et al.; Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346(21):1616–1622. doi:10.1056/NEJMoa012158.12023993
   PubMed Web of Science ®Google Scholar
• Chai X, Friebel TM, Singer CF, et al. Use of risk-reducing surgeries in a prospective cohort of 1499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2014;148(2):397–406. doi:10.1007/s10549-014-3134-025311111
   PubMed Web of Science ®Google Scholar
• Turner NC, Telli ML, Rugo HS, et al. A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). Clin Cancer Res. 2019;25(9):2717–2724. doi:10.1158/1078-0432.CCR-18-189130563931
   PubMed Web of Science ®Google Scholar
• Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018;379(8):753–763. doi:10.1056/NEJMoa180290530110579
   PubMed Web of Science ®Google Scholar
• Turk AA, Wisinski KB. PARP inhibitors in breast cancer: bringing synthetic lethality to the bedside. Cancer. 2018;124(12):2498–2506. doi:10.1002/cncr.3130729660759
   PubMed Web of Science ®Google Scholar
• Garufi G, Palazzo A, Paris I, et al. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors. Expert Opin Pharmacother. 2020;21(6):687–699. doi:10.1080/14656566.2020.172495732052646
   PubMed Web of Science ®Google Scholar
• Fitzpatrick A, Tutt A. Controversial issues in the neoadjuvant treatment of triple-negative breast cancer. Ther Adv Med Oncol. 2019;11:1758835919882581. doi:10.1177/175883591988258131700549
   PubMed Web of Science ®Google Scholar
• Garutti M, Pelizzari G, Bartoletti M, et al. Platinum Salts in Patients with Breast Cancer: a Focus on Predictive Factors. Int J Mol Sci. 2019;20(14):3390. doi:10.3390/ijms20143390
   PubMed Web of Science ®Google Scholar
• Taylor VJ, Barnes PJ, Godwin SC, Bethune GC. Assessment of HER2 using the 2018 ASCO/CAP guideline update for invasive breast cancer: a critical look at cases classified as HER2 2+ by immunohistochemistry. Virchows Arch. 2021. doi:10.1007/s00428-021-03034-4
   Web of Science ®Google Scholar
• Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402–2416. doi:10.1001/jama.2017.711228632866
   PubMed Web of Science ®Google Scholar
• Greenup R, Buchanan A, Lorizio W, et al. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol. 2013;20(10):3254–3258. doi:10.1245/s10434-013-3205-123975317
   PubMed Web of Science ®Google Scholar
• Ryu JM, Choi HJ, Kim I, et al. Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea. Breast Cancer Res Treat. 2019;173(2):385–395. doi:10.1007/s10549-018-5015-430350268
   PubMed Web of Science ®Google Scholar
• Bidoli E, Virdone S, Hamdi-Cherif M, et al. Worldwide Age at Onset of Female Breast Cancer: a 25-Year Population-Based Cancer Registry Study. Sci Rep. 2019;9(1):14111. doi:10.1038/s41598-019-50680-531575963
   PubMed Web of Science ®Google Scholar
• Abdel-Razeq H, Mansour A, Jaddan D. Breast cancer care in Jordan. JCO Glob Oncol. 2020;6:260–268. doi:10.1200/JGO.19.0027932083950
   PubMedGoogle Scholar
• Johnson E. Breast cancer racial differences before age 40-implications for screening. J Nat Med Assoc. 2002;94:149–156.
   PubMed Web of Science ®Google Scholar
• Abdel-Razeq H, Al-Omari A, Zahran F, Arun B. Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan. BMC Cancer. 2018;18(1):152. doi:10.1186/s12885-018-4079-129409476
   PubMed Web of Science ®Google Scholar
• Abdel-Razeq H, Abujamous L, Jadaan D. Patterns and Prevalence of Germline BRCA1 and BRCA2 Mutations among High-Risk Breast Cancer Patients in Jordan: a Study of 500 Patients. J Oncol. 2020;2020:8362179. doi:10.1155/2020/836217932733560
   PubMed Web of Science ®Google Scholar
• El Saghir NS, Zgheib NK, Assi HA, et al. BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer. Oncologist. 2015;20(4):357–364. doi:10.1634/theoncologist.2014-036425777348
   PubMed Web of Science ®Google Scholar
• Copson ER, Maishman TC, Tapper WJ, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 2018;19(2):169–180. doi:10.1016/S1470-2045(17)30891-429337092
   PubMed Web of Science ®Google Scholar
• Baretta Z, Mocellin S, Goldin E, Olopade OI, Huo D. Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis. Medicine. 2016;95(40):e4975. doi:10.1097/MD.000000000000497527749552
   PubMed Web of Science ®Google Scholar
• Schmidt MK, van den Broek AJ, Tollenaar RA, et al. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women. J Natl Cancer Inst. 2017;109:8. doi:10.1093/jnci/djw329
   Google Scholar
• Wang YA, Jian JW, Hung CF, et al. Germline breast cancer susceptibility gene mutations and breast cancer outcomes. BMC Cancer. 2018;18(1):315. doi:10.1186/s12885-018-4229-529566657
   PubMed Web of Science ®Google Scholar